Therapy-related MDS

preview_player
Показать описание
Uma Borate, MD, of the Oregon Health & Science University, Portland, OR, discusses therapy-related myelodysplastic syndromes (MDS) and their under-representation in historic MDS trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Uma Borate
  3. Institution: Oregon Health
  4. Event: VJVirtual
  5. Event: EHA 2020
  6. Format: Interview
Рекомендации по теме
Therapy-related MDS 0:01:58

Therapy-related MDS

What are the 0:07:40

What are the recent insights into therapy-related MDS?

The Role of 0:06:50

The Role of BMT in Treatment-Related MDS and AML

What factors contribute 0:02:06

What factors contribute to the development of therapy-related AML or MDS?

Mutations in MDS 0:56:23

Mutations in MDS - Prognostic and Therapeutic Implications

My approach to 0:33:47

My approach to MDS management

Myelodysplastic syndromes - 0:06:33

Myelodysplastic syndromes - causes, symptoms, diagnosis, treatment, pathology

Innovations in MDS 0:01:36

Innovations in MDS and AML treatment

mefenamic acid and 0:03:01

mefenamic acid and paracetamol suspension | dolopar mds syrup | pet dard ka dawai | syrup

What is the 0:02:35

What is the Best Treatment for MDS?

What are the 0:02:27

What are the treatment options for MDS-related anemia?

MDS/MPN 0:10:30

MDS/MPN

What is the 0:01:39

What is the prognosis for MDS-related anemia? How is prognosis determined?

Myelodysplastic Syndrome (MDS) 0:10:41

Myelodysplastic Syndrome (MDS) - What is the Treatment?

Recent advances in 0:02:40

Recent advances in CAR-T therapy for MDS

Expanding treatment options 0:01:13

Expanding treatment options for AML to patients with MDS

MDS/AML Overlap and 0:09:29

MDS/AML Overlap and Novel Therapies with Dr. Naval Daver

Treating AML with 0:08:25

Treating AML with MDS-related Changes

Understanding Higher Risk 1:13:29

Understanding Higher Risk MDS and Transtion to AML

How serious a 0:03:38

How serious a cancer is MDS? What is the prognosis for MDS?

Can early treatment 0:01:24

Can early treatment for MDS prevent progression to AML? #AML

A Unified Approach 0:21:55

A Unified Approach to Lower Risk MDS: Standard and Emerging Therapies

Etiology and genetic 0:03:03

Etiology and genetic profile of t-MDS

Myth/Fact: What foods 0:00:43

Myth/Fact: What foods can I eat during treatment? | Taryn Prado, MDS, Clinical Dietitian